ivWatch Emphasizes Surveillance Monitoring Benefits to Nurse Leaders at AONE

SAN DIEGO, March 28, 2019 – ivWatch will showcase their solution that aids in the early detection of a common complication of peripheral intravenous (IV) therapy at the 2019 American Organization of Nurse Executives (AONE) Annual Meeting and Exposition on April 10-13, 2019 in San Diego. As part of ongoing efforts to educate on the prevalence of IV complications and the importance of surveillance monitoring to improve patient safety, the company will host open in-booth presentations for attendees to learn more about the economic impacts of peripheral IV infiltration/extravasation injuries.

The session, “Infiltration Impact on Quality and Cost of Care” facilitated by Susan Brown MSN, MSED, VA-BC, the chief nursing officer at ivWatch, will repeat in the company’s booth (#412) during regular exhibition hall hours on:

  • Thursday, April 11: 10:00 a.m. and 12:30 p.m.
  • Friday, April 12: 10:00 a.m. and 12:30 p.m.

“Complications from peripheral IV’s have recently been addressed as a systemic issue facing health systems by the independent patient-safety organization, ECRI Institute, in their Top 10 Patient Safety Concerns for 2019 report*,” said Brown. “I am thrilled to have the opportunity to speak with nursing leadership from across the country on the new advancements in vascular access, and how to harness technology to improve quality and outcomes in this area.”

Additionally, the ivWatch Model 400 will be featured in-booth. The first-of-its-kind continuous monitoring device offers early detection of infiltrations/extravasations, minimizing the risks of IV therapy.

To learn more about ivWatch and upcoming event participation, visit www.ivWatch.com/events/.

*https://www.ecri.org/landing-top-10-patient-safety-concerns-2019

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: Infusion Pump Misconceptions

ivWatch on How Infusion Pump Companies Risk Patient Safety

ivWatch Executive Vice President of Sales and Business Development, Scott Hensley, addresses an infusion pump pressure alarm misconception in the area of infiltration detection, and its potential for patient harm in the MedTech Intelligence article, “Product Myths Put Patient Safety at Risk.” He discusses the importance of transparency from the medical device industry to hospitals, so they are best equipped to use technology to impact and provide better clinical outcomes for the patient. Read the full article here.

In the News: Health Care Heroes Award

ivWatch Chief Medical Officer, Dr. Brian Clare, was named a 2019 Health Care Hero for the ‘Innovations in Health Care’ category. Read more on this special report by Inside Business here.

ivWatch Chief Medical Officer Gains Health Care Hero Title

Brian Clare, M.D. recognized for business pursuits and philanthropic efforts

HAMPTON, Va., March 4, 2019 – Brian Clare, M.D. chief medical officer and member of the Board of Directors at ivWatch, a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, gained recognition as an Inside Business 2019 Health Care Hero during the publication’s annual breakfast March 4 at Norfolk Waterside Marriott. Dr. Clare was recognized as the winner in the ‘Innovations in Health Care’ category for his efforts during his long-standing medical career as an emergency medicine physician and for his work locally helping companies gain critical access to resources.

“Dr. Clare is all business when it comes to medicine,” remarked program judge Kathryn Barrett of Barrett Communications and former WVEC-TV medical editor.

The Health Care Heroes awards epitomize the spirit embodied in the word “hero” in the delivery of health care in the Hampton Roads community; Clare’s reach extends far beyond. Notable achievements include creating one of the first Scribe companies in the United States helping physicians with documentation overburden, and helping secure regulatory clearance for the ivWatch Model 400, a medical device that offers hospitals and health care facilities a means to protect patients from a common complication of IV therapy.

“Brian has been very entrepreneurial in medicine and on the leading edge of developing new markets to correct health care inefficiencies,” said Gary Warren, president and CEO of ivWatch. “Brian’s guidance has been instrumental in helping us secure many of our most important milestones.”

In addition to his advisory roles at ivWatch and other organizations based in Hampton Roads, Clare leads the board of Richmond-based non-profit World Pediatric Project as Chairman, providing life-saving care for critically ill children in the Caribbean and Central America.

To learn more about ivWatch and their leadership team, visit https://www.ivwatch.com/about-us/.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

Infusion Nurses Society Leader Discusses Improving Care with ivWatch CEO

Pioneering efforts to address a common IV therapy complication brought into focus at upcoming association programs

HAMPTON, Va., February 6, 2019 – Several nursing associations have incorporated ivWatch representatives and customers in educational programming to present the latest advances in using sensor technology to identify peripheral IV infiltration/extravasation events earlier than ever before to reduce patient injury.

The Infusion Nurses Society (INS) ‘Talking in Vein’ podcast series is part of the association’s learning center and a forum to discuss infusion-related topics with clinical experts, patient advocates and industry leaders. Launching today is a show with guests Mary Alexander MA, RN, CRNI, CAE, FAAN, CEO of Infusion Nurses Society and Gary Warren, president and CEO of ivWatch. The podcast, “Infiltration: Not What We Thought It Was,” reviews misconceptions about IV failure. During the show Warren discusses how technology can impact and provide better clinical outcomes but asserts it should not replace clinical critical thinking.

In her final remarks, Alexander concludes, “It’s helpful that devices such as ivWatch will warn us of an impending infiltration, however I can’t stress enough the importance of nursing assessment and patient feedback. I do believe there is a nice marriage between practice and technology, and I think it’s important that we’ve got the right balance with the two.”

The discussion showcases the willingness of professional associations and medical device manufacturers to work together to review the real-world implications of novel technology. Additional upcoming events where experts will share their work combating the potential for injury from peripheral IV infiltration/extravasation include:

  • On February 13, Gregory Schears, MD, a pediatric intensivist and anesthesiologist at the Mayo Clinic will facilitate a live webinar session “Short Peripheral Catheter Infiltration: Minimizing Risks to Improve Outcomes,” hosted by the Infusion Nurses Society.
  • On April 25, vascular access leaders from Cincinnati Children’s Hospital Medical Center, Sylvia Rineair MSHA, BSN, RN, VA-BC and Darcy Doellman MSN, RN, CRNI, VA-BC, will speak at the 2019 American Nurses Association (ANA) Quality and Innovation Conference. They will discuss a quality improvement project including clinical studies and deployment of ivWatch technology to reduce patient harm from peripheral IV complications during the concurrent session “Improving the Safety of Peripheral IVs with Novel Technology.” 
  • On April 26, ivWatch Chief Nursing Officer (CNO), Susan Brown joins Jamie Carter BSN, RN, patient care services director at Children’s Hospital of the Kings Daughters at the Society of Pediatric Nurses (SPN) 29th Annual Conference. The joint podium presentation will review how the institution reduced severe peripheral IV infiltration/extravasation events through nurse education and ivWatch technology.

Through educational initiatives like these along with sponsorship of the platform myIV.com, ivWatch showcases continued commitment to improving patient safety and outcomes. To learn more about ivWatch and upcoming event participation, visit www.ivWatch.com/events/.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Announces Additional Global Distribution Partner

HAMPTON, Va., December 11, 2018 – ivWatch, the only provider of continuous patient monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently entered into a distribution agreement with Sedeer Medical Services. Sedeer Medical Services is a major provider and distributor of medical and health care products in Qatar.

“Qatar’s health sector has an exceptional international reputation for offering quality medical care,” said Babu Kupparayil, managing director at Sedeer Medical. “We’re eager to help institutions meet their health care visions by offering the most advanced technology allowing better patient outcomes during IV therapy.”

Upon completion of regulatory approval requirements, Sedeer Medical will distribute and provide training and support for the ivWatch Model 400 patient monitor to new customers as the exclusive distributor in Qatar.

“With a joint mission of working to set new standards of care in the field of quality health care, we are confident Sedeer Medical will be successful in introducing ivWatch breakthrough technology to hospitals and facilities in search of the best solution for early detection of peripheral IV leakage,” said Scott Hensley, vice president of sales and business development at ivWatch.

For further information about ivWatch and their industry partners, visit  www.ivwatch.com/about-us/partnerships/.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCwww.ivwatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest